Using technology to address issues of diversity and inclusion across the drug development lifecycle.
Improving diversity and inclusion in life science is more than just the right thing to do – there’s also a sound business imperative to do so.
Diversity in clinical trial recruitment is a significant shortfall for life science companies, with a number of barriers to participation excluding underserved communities.
“53% of non-Hispanic white participants said that they trusted their health professionals ‘a lot,’ compared with 37% for non-Hispanic black participants and 36% for Hispanic participants.”
Technologies including artificial intelligence, network analytics, social listening, and virtual asynchronous engagement are helping to remove these barriers to trial participation.
An AI-enhanced trial at Cedars-Sinai identified 16 candidates in one hour, while a human-based approach found two people in six months.
Social media is already being used for patient recruitment on 11% of clinical trials globally, where this activity is underpinned by some level of online media monitoring. – PREVENTCANCER.ORG